Markets

Why Puma Biotechnology (PBYI) Could Be Positioned for a Slump - Tale of the Tape

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Puma Biotechnology, Inc. ( PBYI ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in PBYI.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 2 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $2.16 a share a month ago to its current level of a loss of $2.51.

Also, for the current quarter, Puma Biotechnology has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 61 cents a share from a loss of 54 cents over the past 30 days.

The stock also has seen some pretty dismal trading lately, as the share price has dropped 12.68% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.

If you are still interested in the Med-Biomed/Gene sector, you may instead consider some better-ranked stocks including ANI Pharmaceuticals, Inc. ( ANIP ), Gilead Sciences Inc . ( GILD ) and Illumina Inc . ( ILMN ). All these stocks hold a Zacks Rank #1 (Strong Buy) and may be better selections at this time.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PBYI GILD ANIP ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More